Related references
Note: Only part of the references are listed.Molecular Classification of Appendiceal Adenocarcinoma
Michael B. Foote et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Rona Yaeger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial
Brandon M. Huffman et al.
JAMA NETWORK OPEN (2023)
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation
Tanios S. Bekaii-Saab et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
Sai-Hong Ignatius Ou et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
Marwan G. Fakih et al.
LANCET ONCOLOGY (2022)
Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer
J. H. Strickler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Histology-Agnostic Drugs: A Paradigm Shift-A Narrative Review
Andre Mansinho et al.
ADVANCES IN THERAPY (2022)
Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation
M. Patel et al.
ANNALS OF ONCOLOGY (2022)
Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
Mohamed E. Salem et al.
JCO PRECISION ONCOLOGY (2022)
Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type
Amin H. Nassar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Angela Lamarca et al.
LANCET ONCOLOGY (2021)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Current standards and future perspectives in adjuvant treatment for biliary tract cancers
Angela Lamarca et al.
CANCER TREATMENT REVIEWS (2020)
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population
Marta Schirripa et al.
CLINICAL COLORECTAL CANCER (2020)
Targeting Krasg12c-mutant cancer with a mutation-specific inhibitor
J. G. Christensen et al.
JOURNAL OF INTERNAL MEDICINE (2020)
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
Vito Amodio et al.
CANCER DISCOVERY (2020)
Targeting MutantKRASin Pancreatic Cancer: Futile or Promising?
Friederike Inga Nollmann et al.
BIOMEDICINES (2020)
RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Targeting the untargetable KRAS in cancer therapy
Pingyu Liu et al.
ACTA PHARMACEUTICA SINICA B (2019)
Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery
Marc Uemura et al.
BMC CANCER (2017)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior et al.
CANCER RESEARCH (2012)